MeiraGTx Holdings Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG596651029
USD
8.60
0.85 (10.97%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

453.05 k

Shareholding (Mar 2025)

FII

18.16%

Held by 45 FIIs

DII

50.95%

Held by 13 DIIs

Promoter

24.10%

How big is MeiraGTx Holdings Plc?

22-Jun-2025

As of Jun 18, MeiraGTx Holdings Plc has a market capitalization of 508.71 million, with net sales of 34.51 million and a net profit of -167.33 million over the latest four quarters. Shareholder's funds are 67.83 million, and total assets amount to 269.75 million as of Dec 24.

As of Jun 18, MeiraGTx Holdings Plc has a market capitalization of 508.71 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 34.51 million, while the sum of Net Profit for the same period is -167.33 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 67.83 million and Total Assets of 269.75 million.

Read More

What does MeiraGTx Holdings Plc do?

22-Jun-2025

MeiraGTx Holdings Plc is a clinical-stage gene therapy company focused on developing treatments for inherited and acquired disorders. As of March 2025, it reported net sales of $2 million and a net loss of $40 million, with a market cap of $508.71 million.

Overview:<BR>MeiraGTx Holdings Plc is a clinical-stage gene therapy company in the Pharmaceuticals & Biotechnology industry, focused on developing gene therapy treatments for inherited and acquired disorders.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -40 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 508.71 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.31 <BR>Return on Equity: -505.54% <BR>Price to Book: 15.37 <BR><BR>Contact Details:<BR>Address: 450 E 29th St Fl 15, NEW YORK NY: 10016-8367 <BR>Tel: 1 646 8607983 <BR>Website: http://meiragtx.com/

Read More

Should I buy, sell or hold MeiraGTx Holdings Plc?

22-Jun-2025

Who are in the management team of MeiraGTx Holdings Plc?

22-Jun-2025

As of March 2022, the management team of MeiraGTx Holdings Plc includes Dr. Keith Harris (Independent Chairman), Dr. Alexandria Forbes (President and CEO), and several Independent Directors: Ms. Ellen Hukkelhoven, Mr. Martin Indyk, Dr. Arnold Levine, Mr. Joel Marcus, and Mr. Neil Mendoza. They are responsible for the company's strategic direction.

As of March 2022, the management team of MeiraGTx Holdings Plc includes the following individuals:<BR><BR>- Dr. Keith Harris, who serves as the Independent Chairman of the Board.<BR>- Dr. Alexandria Forbes, who is the President, Chief Executive Officer, and Director.<BR>- Ms. Ellen Hukkelhoven, an Independent Director.<BR>- Mr. Martin Indyk, an Independent Director.<BR>- Dr. Arnold Levine, an Independent Director.<BR>- Mr. Joel Marcus, an Independent Director.<BR>- Mr. Neil Mendoza, an Independent Director. <BR><BR>This team is responsible for guiding the strategic direction of the company.

Read More

Is MeiraGTx Holdings Plc overvalued or undervalued?

20-Sep-2025

As of August 7, 2019, MeiraGTx Holdings Plc is considered risky due to its overvaluation and poor financial metrics, including a Price to Book Value of 14.57, negative EV to EBITDA, and significantly low ROCE and ROE, despite a strong year-to-date return of 31.20% compared to the S&P 500's 12.22%.

As of 7 August 2019, the valuation grade for MeiraGTx Holdings Plc moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued given its significant negative performance metrics, including a Price to Book Value of 14.57 and an EV to EBITDA of -3.36. Additionally, the company's ROCE and ROE are alarmingly low at -366.71% and -505.54%, respectively, which further supports the overvaluation thesis.<BR><BR>In comparison to its peers, MeiraGTx's EV to EBITDA ratio of -4.4399 is worse than Voyager Therapeutics, which stands at -0.2378, and MaxCyte at -0.5242. Furthermore, while MeiraGTx has shown a strong YTD return of 31.20% compared to the S&P 500's 12.22%, its long-term performance is concerning, with a 5-year return of -40.95% versus the S&P 500's 96.61%. This discrepancy highlights the risks associated with investing in MeiraGTx Holdings Plc.

Read More

Is MeiraGTx Holdings Plc technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, MeiraGTx Holdings Plc shows a mildly bullish trend overall, despite mixed signals from various indicators, suggesting caution in investment decisions.

As of 10 October 2025, the technical trend for MeiraGTx Holdings Plc has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals. The Bollinger Bands and Dow Theory both show a mildly bullish stance on the weekly and monthly time frames. Daily moving averages are also mildly bullish. However, the KST shows a bearish signal weekly but bullish monthly, and the OBV is mildly bullish weekly but mildly bearish monthly. Overall, the indicators suggest a mildly bullish stance, though the mixed signals indicate caution. There is no available return data for comparison with the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate -199.29% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -45.66
2

Negative results in Jun 25

3

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 601 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

14.95

stock-summary
Return on Equity

-5,321.11%

stock-summary
Price to Book

203.02

Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Jun 2025)
Net Profit:
-39 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.33%
0%
17.33%
6 Months
55.23%
0%
55.23%
1 Year
37.6%
0%
37.6%
2 Years
59.85%
0%
59.85%
3 Years
34.8%
0%
34.8%
4 Years
-50.97%
0%
-50.97%
5 Years
-38.48%
0%
-38.48%

MeiraGTx Holdings Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
17.79%
EBIT Growth (5y)
-199.29%
EBIT to Interest (avg)
-45.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.16
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
79.29%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
14.57
EV to EBIT
-3.10
EV to EBITDA
-3.36
EV to Capital Employed
11.36
EV to Sales
14.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-366.71%
ROE (Latest)
-505.54%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 31 Schemes (6.78%)

Foreign Institutions

Held by 45 Foreign Institutions (18.16%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 94.74% vs -91.12% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 3.00% vs -1.52% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.70",
          "val2": "1.90",
          "chgp": "94.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.60",
          "val2": "-38.50",
          "chgp": "-8.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.00",
          "val2": "3.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-38.80",
          "val2": "-40.00",
          "chgp": "3.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-12,135.70%",
          "val2": "-21,597.10%",
          "chgp": "946.14%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 137.86% vs -11.95% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -75.95% vs 35.19% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33.30",
          "val2": "14.00",
          "chgp": "137.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-151.40",
          "val2": "-123.30",
          "chgp": "-22.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "13.30",
          "val2": "13.20",
          "chgp": "0.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-147.80",
          "val2": "-84.00",
          "chgp": "-75.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,934.40%",
          "val2": "-9,778.20%",
          "chgp": "484.38%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
3.70
1.90
94.74%
Operating Profit (PBDIT) excl Other Income
-41.60
-38.50
-8.05%
Interest
3.00
3.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-38.80
-40.00
3.00%
Operating Profit Margin (Excl OI)
-12,135.70%
-21,597.10%
946.14%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 94.74% vs -91.12% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 3.00% vs -1.52% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
33.30
14.00
137.86%
Operating Profit (PBDIT) excl Other Income
-151.40
-123.30
-22.79%
Interest
13.30
13.20
0.76%
Exceptional Items
0.00
0.50
-100.00%
Consolidate Net Profit
-147.80
-84.00
-75.95%
Operating Profit Margin (Excl OI)
-4,934.40%
-9,778.20%
484.38%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 137.86% vs -11.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -75.95% vs 35.19% in Dec 2023

stock-summaryCompany CV
About MeiraGTx Holdings Plc stock-summary
stock-summary
MeiraGTx Holdings Plc
Pharmaceuticals & Biotechnology
MeiraGTx Holdings plc is a clinical-stage gene therapy company. The Company develops gene therapy treatments for a range of inherited and acquired disorders. It is focused on developing therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia, radiation treatment for head and neck cancers and neurodegenerative diseases, such as amyothrophic lateral sclerosis (ALS). It is also developing transformative technology to enable the use of small molecules to turn gene therapy product candidates on and off. It is focused on three areas of unmet medical needs, including inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Its product candidates include AAV-CNGB3, AAV-CNGA3, AAV-RPGR, AAV-RPE65, AAV-AQP1 and AAV-UPF1.
Company Coordinates stock-summary
Company Details
450 E 29th St Fl 15 , NEW YORK NY : 10016-8367
stock-summary
Tel: 1 646 8607983
stock-summary
Registrar Details